Literature DB >> 19824919

T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection.

Karen Smith Korsholm1, Rune V Petersen, Else Marie Agger, Peter Andersen.   

Abstract

Vaccine adjuvants activate the innate immune system and thus influence subsequent adaptive T-cell responses. However, little is known about the initial immune mechanisms preceding the adjuvant-induced differentiation of T-helper (Th) cells. The effect of a T-helper 1 (Th1) adjuvant, dimethyldioctadecylammonium liposomes with monophosphoryl lipid-A (DDA/MPL), and a T-helper 2 adjuvant, aluminium hydroxide [Al(OH)(3)], on early, innate chemotactic signals and inflammatory cell influx at the site of injection was therefore investigated. Injection of the adjuvants into the peritoneal cavity of mice demonstrated distinct differences in the magnitude, quality and kinetics of the response. The inflammatory response to DDA/MPL was prominent, inducing high local levels of pro-inflammatory cytokines, chemokines and a pronounced inflammatory exudate consisting of neutrophils, monocytes/macrophages and activated natural killer cells. This was in contrast to the response induced by Al(OH)(3), which, although sharing some of the early chemokine signals, was more moderate and consisted almost exclusively of neutrophils and eosinophils. Notably, Al(OH)(3) specifically induced the release of a significant amount of interleukin (IL)-5, whereas DDA/MPL induced high amounts of tumour necrosis factor-alpha (TNF-alpha), IL-1alpha and IL-6. Finally, a microarray analysis confirmed that the effect of DDA/MPL was broader with more than five times as many genes being specifically up-regulated after injection of DDA/MPL compared with Al(OH)(3). Thus, the adjuvants induced qualitatively distinct local inflammatory signals early after injection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824919      PMCID: PMC2807488          DOI: 10.1111/j.1365-2567.2009.03164.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  58 in total

Review 1.  (How) do aluminium adjuvants work?

Authors:  James M Brewer
Journal:  Immunol Lett       Date:  2005-08-30       Impact factor: 3.685

2.  goCluster integrates statistical analysis and functional interpretation of microarray expression data.

Authors:  Gunnar Wrobel; Frédéric Chalmel; Michael Primig
Journal:  Bioinformatics       Date:  2005-07-14       Impact factor: 6.937

3.  Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells.

Authors:  M Rescigno; S Citterio; C Thèry; M Rittig; D Medaglini; G Pozzi; S Amigorena; P Ricciardi-Castagnoli
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

4.  Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey.

Authors:  François Verdier; Roger Burnett; Claire Michelet-Habchi; Philippe Moretto; Françoise Fievet-Groyne; Elisabeth Sauzeat
Journal:  Vaccine       Date:  2005-02-03       Impact factor: 3.641

5.  Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins.

Authors:  Susu M Zughaier; Shanta M Zimmer; Anup Datta; Russell W Carlson; David S Stephens
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

6.  Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.

Authors:  Jan A M Langermans; T Mark Doherty; Richard A W Vervenne; Tridia van der Laan; Konstantin Lyashchenko; Rena Greenwald; Else Marie Agger; Claus Aagaard; Horst Weiler; Dick van Soolingen; Wilfried Dalemans; Alan W Thomas; Peter Andersen
Journal:  Vaccine       Date:  2005-04-15       Impact factor: 3.641

7.  TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development.

Authors:  Jie Sun; Matthew Walsh; Alejandro V Villarino; Laura Cervi; Christopher A Hunter; Yongwon Choi; Edward J Pearce
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

8.  Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming.

Authors:  Alfonso Martín-Fontecha; Lindy L Thomsen; Sara Brett; Craig Gerard; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2004-11-07       Impact factor: 25.606

9.  In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to freund's complete adjuvant, but continues to induce T helper 2 cytokine production.

Authors:  J M Brewer; M Conacher; A Satoskar; H Bluethmann; J Alexander
Journal:  Eur J Immunol       Date:  1996-09       Impact factor: 5.532

10.  Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway.

Authors:  A D McLellan; R V Sorg; L A Williams; D N Hart
Journal:  Eur J Immunol       Date:  1996-06       Impact factor: 5.532

View more
  35 in total

Review 1.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

2.  Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Authors:  Douglas M Herrin; Emily E Coates; Pamela J Costner; Troy J Kemp; Martha C Nason; Kapil K Saharia; Yuanji Pan; Uzma N Sarwar; Lasonji Holman; Galina Yamshchikov; Richard A Koup; Yuk Ying S Pang; Robert A Seder; John T Schiller; Barney S Graham; Ligia A Pinto; Julie E Ledgerwood
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

4.  Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis.

Authors:  Yuangang Liu; Zhiping Wang; Rachel De La Torre; Ashley Barling; Takahiro Tsujikawa; Noah Hornick; Jon Hanifin; Eric Simpson; Yun Wang; Emily Swanzey; Aaron Wortham; Hao Ding; Lisa M Coussens; Molly Kulesz-Martin
Journal:  J Invest Dermatol       Date:  2016-10-05       Impact factor: 8.551

Review 5.  Enhancing vaccine effectiveness with delivery technology.

Authors:  Marie Beitelshees; Yi Li; Blaine A Pfeifer
Journal:  Curr Opin Biotechnol       Date:  2016-03-06       Impact factor: 9.740

6.  A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Authors:  William M Gwinn; Brandi T Johnson; Shaun M Kirwan; Ashley E Sobel; Soman N Abraham; Michael D Gunn; Herman F Staats
Journal:  Vaccine       Date:  2013-01-23       Impact factor: 3.641

Review 7.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

8.  Combination of Mycobacterium indicus pranii and Heat-Induced Promastigotes Cures Drug-Resistant Leishmania Infection: Critical Role of Interleukin-6-Producing Classical Dendritic Cells.

Authors:  Somaditya Dey; Debarati Mukherjee; Sirin Salma Sultana; Suvadip Mallick; Aritri Dutta; Joydip Ghosh; Aabid Hussain; Biswajyoti Sarkar; Supratim Mandal; Pradyumna Patra; Bhaskar Saha; Chiranjib Pal
Journal:  Infect Immun       Date:  2020-05-20       Impact factor: 3.441

9.  The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.

Authors:  Simone C de Cassan; Emily K Forbes; Alexander D Douglas; Anita Milicic; Bijender Singh; Puneet Gupta; Virander S Chauhan; Chetan E Chitnis; Sarah C Gilbert; Adrian V S Hill; Simon J Draper
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

Review 10.  Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines.

Authors:  Saed Abbasi; Satoshi Uchida
Journal:  Pharmaceutics       Date:  2021-05-01       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.